The safety and tolerability of regadenoson in patients with end-stage renal disease: The first prospective evaluation
Authors:
- 1 April 2013
- journal article
- research article
- Published by Elsevier in Journal of Nuclear Cardiology
- Vol. 20 (2) , 205-213
Abstract
No abstract availableKeywords
This publication has 27 references indexed in Scilit:
- A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney diseaseJournal of Nuclear Cardiology, 2012
- Racial differences in chronic kidney disease (CKD) and end-stage renal disease (ESRD) in the United States: a social and economic dilemmaClinical Nephrology, 2011
- RegadenosonAmerican Journal of Cardiovascular Drugs, 2010
- Effects of Age, Gender, Obesity, and Diabetes on the Efficacy and Safety of the Selective A2A Agonist Regadenoson Versus Adenosine in Myocardial Perfusion ImagingJACC: Cardiovascular Imaging, 2008
- Regadenoson Pharmacokinetics and Tolerability in Subjects With Impaired Renal FunctionThe Journal of Clinical Pharmacology, 2007
- Initial Clinical Experience With Regadenoson, a Novel Selective A2AAgonist for Pharmacologic Stress Single-Photon Emission Computed Tomography Myocardial Perfusion ImagingJACC, 2005
- Comparative Profile of Vasodilation by CVT-3146, a Novel A2A Receptor Agonist, and Adenosine in Conscious DogsThe Journal of Pharmacology and Experimental Therapeutics, 2003
- Standardized Myocardial Segmentation and Nomenclature for Tomographic Imaging of the HeartCirculation, 2002
- Electrocardiographic abnormalities in patients receiving hemodialysisAmerican Heart Journal, 1996
- Cardiac Arrhythmias in Hemodialysis PatientsNephron, 1989